Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
LeukemiaLymphomaMyelomaHodgkin's Disease
Interventions
BIOLOGICAL

NK-92 cells

"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:~* Level I: 1x10\^9 cells/m\^2~* Level II: 3x10\^9 cells/m\^2~* Level III: 5x10\^9 cells/m\^2"

Trial Locations (1)

M5G 2M9

Princess Margaret Hospital, Toronto

All Listed Sponsors
lead

University Health Network, Toronto

OTHER

NCT00990717 - Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | Biotech Hunter | Biotech Hunter